This week Generics Bulletin has published its annual Top 50 ranking by turnover of the world's leading generics and biosimilars players. You can read the first of our four articles here:

In this exclusive two-part interview, @Amgen's Chad Pettit, @AmgenBiosim commercial lead, talks to @Genericbulletin about the firm’s “unique perspective” on biosimilars, including how competition to Humira is expected to signal a major shift in the US biosimilars landscape.

At an eventful time for US biosimilars, a fresh wave of players entering the market is expected to both increase competition and broaden access, says AmerisourceBergen’s (@Healthcare_ABC’s) senior vice president for global emerging therapies and channel strategy, Beth McMahon.

In an exclusive two-part interview, @SamsungBioepis development division leader Kyung-ah Kim and @biogen global head of biosimilars Ian Henshaw discuss how the firms are aiming to capitalize on their launch of the world’s first Lucentis biosimilar, Byooviz, in the US.

In this two-part interview, I talk to @hikmapharma CEO Siggi Olafsson about how Hikma expects to maintain its deal-making momentum, future plans for US biosimilars, and how it is positioned to deal with pricing pressures and increased competition on some of its key generics.

Sonia Oskouei, @cardinalhealth VP of biosimilars, talks about how real-world evidence and education can build confidence in biosimilars, as well as the ongoing struggle against misinformation and need for clarity over concepts such as interchangeability and unbranded biologics.

A major biosimilars deal between @Bioconlimited and @ViatrisInc to kick off this week:

With key milestones on the horizon for US biosimilars in 2022 and 2023, @cardinalhealth VP of biosimilars Sonia Oskouei explains how the industry can best position itself to take advantage of upcoming opportunities, including potentially a global leadership role in ophthalmology.

In an exclusive interview with Generics Bulletin, the @USBiosimilars Forum’s executive director Julie Reed sets out the group’s priorities and explains how its diverse membership is helping to position it as a leading voice for the US biosimilars industry.

In the second part of an exclusive two-part interview with Generics Bulletin, @alvotechpr founder and chairman @RobertWessman sets out the firm’s expectations for its rival to Humira as it continues to battle AbbVie in US litigation over its higher-strength adalimumab biosimilar.

Alvotech founder and chairman @RobertWessman tells Generics Bulletin how the firm plans to move forward following recently-revealed plans for a SPAC merger that will provide fresh impetus for the biosimilars specialist with an injection of almost $500m in funding. @alvotechpr

With the first approved rival to Lucentis in both the EU and US, @SamsungBioepis is laying the groundwork for biosimilars to break into ophthalmology ahead of launching its Byooviz version of ranibizumab, explains vice-president of commercial strategy Josh Lee.

With the Big Give, @ihp_uk is raising money to get vital medicine to people who need it. For every £1 donated, IHP can send £20 worth of medicine. bit.ly/32MXgQI generics.pharmaintelligence.…

In this interview, CEO Michael Goettler provides an update on the progress made by @ViatrisInc in its first year, also previewing the detailed strategy that will be unveiled at the firm’s upcoming investor day and underlining the importance of biosimilars and complex generics.